The Development of Menin Inhibitors in AML and ALL

H&O  What are menin inhibitors, and how do they function in the context of acute myeloid leukemia/acute lymphoblastic leukemia? GI  Menin inhibitors are a new form […]

Epcoritamab, a Promising Therapy for Richter Syndrome?

H&O  What defines Richter syndrome? AK  Richter syndrome (RS), also known as Richter transformation, refers to the development of an aggressive lymphoma in the setting of […]

The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma

H&O  What is glofitamab, and how does it work for patients with relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? LF  Glofitamab (Columvi, Genentech) is […]

Update on the CAPTIVATE Trial of Ibrutinib Plus Venetoclax

H&O  Could you describe the impetus for and design of the CAPTIVATE trial? TS  The large, multicenter, phase 2 CAPTIVATE trial focused on patients with chronic […]

Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma

H&O  What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB  Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]

Is Blinatumomab Now Standard of Care Consolidation for Patients With ALL?

H&O  What is blinatumomab and how does it work in treating acute lymphocytic leukemia (ALL)? SL  Blinatumomab (Blincyto, Amgen), which is classified as a bispecific antibody, […]

Quizartinib, the Next FLT3 Inhibitor

H&O  What are FMS-like tyrosine kinase 3 (FLT3) inhibitors, and how have they affected the treatment of patients with acute myeloid leukemia (AML)? JC  FLT3 mutations […]

Momelotinib, the Next JAK2 Inhibitor?

H&O What is momelotinib and how does it work? LM Momelotinib is a selective inhibitor of Janus kinase 1 (JAK1), JAK2, and activin A receptor type […]

Zandelisib and B-Cell Lymphomas

H&O  How does zandelisib work?  AZ  Zandelisib is a phosphoinositide 3-kinase delta (PI3K-δ) inhibitor with a long half-life. PI3K comes in multiple isoforms, including alpha, beta, […]

Noncovalent BTK Inhibitors in B-Cell Lymphoma

H&O  What are the limitations of standard (covalent) BTK inhibitors in B-cell malignancies? CC  The 2 major limitations of covalent Bruton’s tyrosine kinase (BTK) inhibitors are […]

Optimizing the Benefits of BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

H&O  Why is the B-cell maturation antigen (BCMA) a good target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? SL  BCMA is an important […]

Targeting the Microbiome to Improve Outcomes in Stem Cell Transplant

H&O  What are the characteristics of a healthy microbiome? DP  A healthy microbiome is dynamic and diverse. It consists of many different types of commensal bacteria—predominantly […]

Key Points From the SHINE Trial in Mantle Cell Lymphoma

H&O  Could you provide some background on mantle cell lymphoma? JT  Mantle cell lymphoma is an uncommon type of lymphoma. It represents approximately 6% of non-Hodgkin […]

Advances in the Classification and Management of Patients With T-Cell Lymphoma

H&O What are the most common types of T-cell lymphoma? LP  T-cell lymphoma is a heterogeneous group of disorders that encompass many subtypes. T-cell lymphomas that […]

Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia

H&O  How was the hyper-CVAD regimen originally used? EJ  The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]

The Future Role of Bispecific Antibodies in Lymphoma

H&O What is the mechanism of action of bispecific antibodies? JA  Bispecific antibodies aim to harness the power of the immune system. These treatments are monoclonal […]

New Approaches to T-Cell Acute Lymphoblastic Leukemia

H&O How common is T-cell acute lymphoblastic leukemia (T-ALL)? DT  ALL is uncommon, accounting for approximately 6700 new diagnoses per year in the United States. Between […]

Insights Into the Management of Patients With Primary Central Nervous System Lymphoma

H&O What is the definition of primary central nervous system (CNS) lymphoma ? CF  Primary CNS lymphoma is referred to as primary diffuse large B-cell lymphoma […]

Evolving Management of Patients With Double-Hit Lymphoma

H&O  What is the definition of double-hit lymphoma? AL  Double-hit lymphoma is an aggressive B-cell lymphoma with MYC translocation and a BCL2 and/or BCL6 translocation. The […]

Recent Data for Acalabrutinib in Chronic Lymphocytic Leukemia

H&O  What type of drug is acalabrutinib? PG  Acalabrutinib (Calquence, AstraZeneca) is a so-called next-generation Bruton’s tyrosine kinase (BTK) inhibitor. The first-generation BTK inhibitor, ibrutinib (Imbruvica, […]